Corticosteroid-related central nervous system side effects

Journal of Pharmacology and Pharmacotherapeutics

Volumn 4, Issue SUPPL.1, 2013, Pages

  Ciriaco, Miriam ^a,b   Ventrice, Pasquale ^a,b   Russo, Gaetano ^c   Scicchitano, Maria ^c   Mazzitello, Giovanni ^d   Scicchitano, Francesca ^a,b   Russo, Emilio ^a,b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b University Hospital of Mater Domini   (Italy)

^c General Hospital Pugliese Ciaccio   (Italy)

^d Presidio Ospedaliero Unico   (Italy)

Author keywords

Adverse effects; central nervous system; corticosteroids; mood; psychosis

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BETA ENDORPHIN; BETAMETHASONE SODIUM PHOSPHATE; CARBAMAZEPINE; CORTICOSTEROID; CORTICOTROPIN; CORTISONE; FLUOXETINE; GABAPENTIN; LAMOTRIGINE; LITHIUM SALT; METHYLPREDNISOLONE; NORADRENALIN; OLANZAPINE; PHENYTOIN; PLACEBO; PREDNISOLONE; PREDNISONE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ABNORMAL BEHAVIOR; ACNE; ADRENAL INSUFFICIENCY; AGITATION; ALLERGY; ANXIETY; APATHY; ATTENTION DISTURBANCE; AUDITORY HALLUCINATION; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; BRAIN ATROPHY; CATARACT; CATATONIA; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE DEFECT; CONCENTRATION LOSS; CONSCIOUSNESS DISORDER; CORTICOSTEROID RELEASE; DELIRIUM; DEPRESSION; DISORIENTATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG COMPETITION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; EMOTIONAL DISORDER; ENDOCRINE DISEASE; EUPHORIA; GLAUCOMA; GROWTH RETARDATION; HALLUCINATION; HUMAN; HYPERACTIVITY; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPOCALCEMIA; HYPOKALEMIA; IMMUNE DEFICIENCY; INCIDENCE; INCREASED APPETITE; INSOMNIA; IRRITABILITY; LANGUAGE DISABILITY; LOW BACK PAIN; MANIA; MEMORY DISORDER; MENTAL DISEASE; MENTAL INSTABILITY; METABOLIC ACIDOSIS; METABOLIC DISORDER; MOOD CHANGE; MOOD DISORDER; MOON FACE; MUSCLE RIGIDITY; MYOPATHY; NEUROTOXICITY; OSTEOPOROSIS; PANCREATITIS; PARANOIA; PARAPHASIA; PEPTIC ULCER; PSYCHOSIS; RESTLESSNESS; REVIEW; RISK FACTOR; SKIN ATROPHY; SLEEP DISORDER; WATER RETENTION; WEIGHT GAIN;

EID: 84889578993     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.120975     Document Type: Review

References (41)

1. Rhen T, Cidlowski JA. Antinflammatory action of glucocorticoids Antiinflammatory Action of Glucocorticoids-New mechanisms for old drugs. N Engl J Med 2005;353:1711-23.
2. Rhen T, Cidlowski JA. Nuclear factor-kB and glucocorticoid receptors. In: Martini L, editor. Encyclopedia of endocrine diseases. Vol.
3. Boston: Elsevier Academic Press; 2004. p. 391-8.
4. The Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther 1972;13:694-8.
5. Wolkowitz OM. Prospective controlled studies of the behavioral and biological effects of exogenous corticosteroids. Psychoneuroendocrinology 1994;19:233-55.
6. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 2000;21:55-89.
7. Marques-Deak A, Cizzaand G, Sternberg E. Brain-immune interactions and disease susceptibility. Mol Psychiatry 2005;10:239-50.
8. Duma D, Jewell CM, Cidlowski JA. Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification. J Steroid Biochem Mol Biol 2006;102:11-21.
9. Bladh LG, Liden J, Dahlman-Wright K, Reimers M, Nilsson S, Okret S. Identification of endogenous glucocorticoid repressed genes differentially regulated by a glucocorticoid receptor mutant able to separate between nuclear factor-kappaB and activator protein-1 repression. Mol Pharmacol 2005;67:815-2.
10. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005;353:1711-23.
11. Van Rossum EF, Lamberts SW. Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog Horm Res 2004;59:333-57.
12. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord 1983;5:319-32.
13. Fietta P, Fietta P, Delsante G. Central nervous system effects of natural and synthetic glucocorticoids. Psychiatry Clin Neurosci 2005;63:613-22.
14. Schacke H, Docke WD, Asadullah K, Ganda JC. Mechanisms of disease 1723 Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23-43.
15. Fardet L, Petersen I, Nazareth I. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. Am J Psychiatry 2012;169:491-7.
16. Falk WE, Mahnke MW, Poskanzer DC. Lithium prophylaxis of corticotropin-induced psychosis. JAMA 1979;241:1011-2.
17. Hall RCW, Popkin MK, Kirkpatrick B. Tricyclic exacerbation of steroid psychosis. J Nerv Ment Dis 1978;166:738-42.
18. Halper JP. Corticosteroids and behavioral disturbances, In: Lin AN. Paget SA, editor. Principles of Corticosteroids Therapy. London: Arnold; 2002. p. 174-201.
19. Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Inês LB, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data. Ann Rheum Dis 2006;65:285-93.
20. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006;55:420-6.
21. Swinburn CR, Wakefield JM, Newman SP, Jones PW. Evidence of prednisolone induced mood change ('steroid euphoria') in patients with chronic obstructive airways disease. Br J Clin Pharmacol 1988;26:709-13.
22. Robinson DE, Harrison-Hansley E, Spencer RF. Steroid psychosis after an intra-articular injection. Ann Rheum Dis 2000;59:927.
23. Benyamin RM, Vallejo R, Kramer J, Rafeyan R. Corticosteroid induced psychosis in the pain management setting. Pain Physician 2008;11:917-20.
24. Wolkowitz OM, Rubinow D, Doran AR, Breier A, Berrettini WH, Kling MA. Prednison effects on neurochemistry and behavior. Preliminary findings. Arch Gen Psychiatry 1990;47:963-8.
25. Ioannou N, Liapi C, Sekeris CE, Palaiologos G. Effects of dexamethasone on K(+)-evoked glutamate release from rat hippocampal slices. Neurochem Res 2003;28:875-81.
26. Coluccia D, Wolf OT, Kollias S, Roozendaal B, Forster A, de Quervain DJ. Glucocorticoid therapy-induced memory deficits: Acute versus chronic effects. J Neurosci 2008;28:3474-8.
27. Bolanos S, Khan D, Hanczyc M, Bauer M, Dhanani N, Brown E. Assessment of mood stat in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales. Ann Allergy Asthma Immunol 2004;92:500-5.
28. Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther 1972;13:694-8.
29. Lewis GP, Jusko WJ, Burke CW, Graves L, Boston collaborative drug surveillance program. Prednisolone side effects and serum protein levels. A collaborative study. Lancet 1971;298:778-81.
30. Bender BG, Lerner JA, Kollasch E. Mood and memory changes in asthmatic children receiving corticosteroids. J Am Acad Child Adolesc Psychiatry 1988;27:720-5.
31. McEwen BS. Allostasis, allostatic load, and the aging nervous system: Role of excitatory amino acids and excitotoxicity. Neurochem Res 2000;25:1219-31.
32. Ling MH, Perry PJ, Tsuang MT. Side effects of corticosteroid therapy. Psychiatric aspects. Arch Psychiatry 1981;38:471-7.
33. Goldstein ET, Preskorn SH. Mania triggered by a steroid nasal spray in a patient with stable bipolar disorder. Am J Psychiatry 1989;146:1076-7.
34. George ME, Sharma V, Jacobson J, Simon S, Nopper AJ. Adverse effects of systemic glucocorticosteroid therapy ininfants with hemangiomas. Arch Dermatol 2004;140:963-9.
35. Kahn D, Stevenson E, Douglas CJ. Effect of sodium valproate in three patients with organic brain syndromes. Am J Psychiatry 1988;145:1010-1.
36. Wada K, Yamada N, Sato T, Suzuki H, Miki M, Lee Y, et al. Corticosteroidinduced psychotic and mood disorders: Diagnosis defined by DSM-IV and clinical pictures. Psychosomatics 2001;42:461-6.
37. Hall RC, Popkin MK, Kirkpatrick B. Tricyclic exacerbation of steroid psychosis. J Nerv Ment Dis 1978;166:738-42.
38. Wyszynski AA, Wyszynski B. Treatment of depression with fluoxetine in corticosteroid dependent central nervous system Sjogren's syndrome. Psychosomatics 1993;34:173-7.
39. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text Revision. Washington, DC: American Psychiatric Press; 2000.
40. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes: A report of 14 cases and a review of the literature. J Affect Disord 1983;5:319-33.
41. Varney NR, Alexander B, Macindoe JH. Reversible steroid dementia in patients without steroid psychosis. Am J Psychiatry 1984;141:369-72.